Open access · OA
via Europe PMC
Diabetes-Associated Cognitive Impairment: Pathophysiology and Emerging Therapies.
Corbali O, Menon P, Corbali HI, Jagannathan R, Levey AI.
Annals of clinical and translational neurology · 2026
Abstract
Diabetes-associated cognitive impairment (DACI) is a common yet underrecognized condition, manifesting along a spectrum from mild cognitive impairment to dementia. DACI encompasses patients who develop vascular dementia (VaD) or Alzheimer's disease (AD) with diabetes as a risk factor; however, in certain patients, particularly those lacking clear VaD or AD features, diabetes may act as a primary driver of neurodegeneration. Mechanistically, DACI can be conceptualized as a neurovascular-metabolic disorder characterized by disruption of the neurovascular unit, impaired cerebral glucose metabolism, brain insulin resistance, and chronic neuroinflammation, contributing to small vessel disease, regional brain atrophy, and accelerated brain aging. In this narrative review, we synthesize current evidence on the clinical and imaging features of DACI, outline key mechanistic pathways linking diabetes to neurodegeneration, and discuss emerging therapeutic strategies, including GLP-1 receptor agonists and SGLT2 inhibitors, with potential neuroprotective effects. Greater recognition of DACI as a neurovascular-metabolic entity may facilitate earlier identification, inform biomarker development, and guide future trials aimed at preserving cognitive function in individuals with diabetes.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- Europe PMC
- DOI
- 10.1002/acn3.70487
- Canonical
- link ↗
- Fetched
- 2026-11-13 MST
Cite this
APA
O, C., P, M., HI, C., R, J., & AI., L. (2026). Diabetes-Associated Cognitive Impairment: Pathophysiology and Emerging Therapies. <em>Annals of clinical and translational neurology</em>. https://doi.org/10.1002/acn3.70487
Vancouver
O C, P M, HI C, R J, AI. L. Diabetes-Associated Cognitive Impairment: Pathophysiology and Emerging Therapies. Annals of clinical and translational neurology. 2026. doi:10.1002/acn3.70487.
BibTeX
@article{corbali2026Diabet,
title = {Diabetes-Associated Cognitive Impairment: Pathophysiology and Emerging Therapies.},
author = {Corbali O and Menon P and Corbali HI and Jagannathan R and Levey AI.},
journal = {Annals of clinical and translational neurology},
year = {2026},
doi = {10.1002/acn3.70487},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Neuroprotection/Neuroprotection (Chichester, England. Print) 2023
Open access · CC-BY
Preserving cognitive function in patients with Alzheimer's disease: The Alzheimer's disease neuroprotection research initiative (ADNRI)
Alzheimer disease and associated disorders 2026
Citation only
Brain Mechanisms Linking Type 2 Diabetes to Alzheimer Disease: A Multimodal Imaging Framework.
Annals of clinical and translational neurology 2026
Open access · OA
Diabetes‐Associated Cognitive Impairment: Pathophysiology and Emerging Therapies
Dementia & Neuropsychologia 2016
Open access · CC-BY
Subjective cognitive decline: The first clinical manifestation of Alzheimer's disease?
Journal of Gerontology and Geriatrics 2024
Open access · CC-BY
Common neurodegenerative pathways in brain aging, cognitive decline, type 2 diabetes & metabolic syndrome
Veterinary sciences 2026
Open access · OA